Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 1;4(8):1112-1115.
doi: 10.1001/jamaoncol.2017.4526.

EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer

Yasuo Oshima  1 , Tetsuya Tanimoto  2 , Koichiro Yuji  1 , Arinobu Tojo  1
Affiliations

EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer

Yasuo Oshima et al. JAMA Oncol. .

Abstract

Importance: Nivolumab and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are now the standard-of-care therapies in non-small cell lung cancer (NSCLC). Although EGFR-TKIs are well understood and have well-defined safety profiles, our experience with immune checkpoint inhibitors is still growing, particularly regarding the use of combinations of different classes of antitumor agents, including both the concomitant and sequential use of such agents.

Objective: To determine whether nivolumab increases EGFR-TKI-associated interstitial pneumonitis (IP).

Design, setting, and participants: A database study of 20 516 participants with NSCLC in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, performed between April 2015 and March 2017.

Main outcomes and measures: We compared the incidence of EGFR-TKI-associated IP in patients receiving and not receiving nivolumab treatment.

Results: The mean (SD) age of participants treated with EGFR-TKI, with and without nivolumab, was 64.4 (15.5) and 68.9 (11.8) years, respectively, and the proportion of men was 40.0% and 53.8%, respectively. Of the 20 516 participants with NSCLC, 985 cases (4.80%; 95% CI, 4.51-5.10) developed IP. Of 5777 patients treated with EGFR-TKI, 265 developed IP (4.59%; 95% CI, 4.06-5.16). Of 70 patients treated with both EGFR-TKI and nivolumab, 18 developed IP (25.7%; 95% CI, 16.0-37.6). The adjusted odds ratio for an interaction between EGFR-TKI and nivolumab was 4.31 (95% CI, 2.37-7.86; P < .001), suggesting the existence of an interaction. When we further stratified the patients by treatment with and without nivolumab, the odds ratio of EGFR-TKI-associated IP in cases with and without nivolumab treatment was 5.09 (95% CI, 2.87-9.03) and 1.22 (95% CI, 1.00-1.47), respectively.

Conclusions and relevance: We found a higher proportion of reports of IP for nivolumab in combination with EGFR-TKI vs treatment with either drug alone. Owing to the limitations of this study, the results warrant further confirmation. However, careful consideration should be given to the possibility of an increased risk of IP when EGFR-TKI is administered in combination with nivolumab, including concomitant and sequential use, and careful monitoring for IP is recommended.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Oshima reports personal fees from Novartis Pharma K.K., personal fees from sanofi K.K., outside the submitted work. Dr Tojo reports grants from Pfizer, grants from Chugai Pharmaceutical, grants from Daiichi Sankyo, grants from Sumitomo Dainippon Pharma, personal fees from Taiho Pharmaceutical, personal fees from Novartis, personal fees from Otsuka Pharmaceutical, personal fees from Sysmex, personal fees from Bristol-Myers Squibb, outside the submitted work. No other disclosures are reported.

Comment in

References

    1. Japanese Society of Medical Oncology http://www.jsmo.or.jp/news/jsmo/20160713.html. Accessed on August 17, 2017.
    1. Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA. 1993;269(21):2765-2768. - PubMed
    1. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20(Suppl C, C40-4). - PubMed
    1. R Development Core Team . (2008). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, http://www.R-project.org. Accessed June 1, 2017.
    1. Shah RR. Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas. Drug Saf. 2016;39(11):1073-1091. - PubMed

MeSH terms